These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine. Tretyakova I; Lukashevich IS; Glass P; Wang E; Weaver S; Pushko P Vaccine; 2013 Feb; 31(7):1019-25. PubMed ID: 23287629 [TBL] [Abstract][Full Text] [Related]
24. Adenoviral-Vectored Mayaro and Chikungunya Virus Vaccine Candidates Afford Partial Cross-Protection From Lethal Challenge in A129 Mouse Model. Campos RK; Preciado-Llanes L; Azar SR; Kim YC; Brandon O; López-Camacho C; Reyes-Sandoval A; Rossi SL Front Immunol; 2020; 11():591885. PubMed ID: 33224148 [TBL] [Abstract][Full Text] [Related]
25. Directed molecular evolution improves the immunogenicity and protective efficacy of a Venezuelan equine encephalitis virus DNA vaccine. Dupuy LC; Locher CP; Paidhungat M; Richards MJ; Lind CM; Bakken R; Parker MD; Whalen RG; Schmaljohn CS Vaccine; 2009 Jun; 27(31):4152-60. PubMed ID: 19406186 [TBL] [Abstract][Full Text] [Related]
28. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits. Metz SW; Martina BE; van den Doel P; Geertsema C; Osterhaus AD; Vlak JM; Pijlman GP Vaccine; 2013 Dec; 31(51):6092-6. PubMed ID: 24099875 [TBL] [Abstract][Full Text] [Related]
29. An immunological profile of Balb/c mice protected from airborne challenge following vaccination with a live attenuated Venezuelan equine encephalitis virus vaccine. Bennett AM; Elvin SJ; Wright AJ; Jones SM; Phillpotts RJ Vaccine; 2000 Sep; 19(2-3):337-47. PubMed ID: 10930689 [TBL] [Abstract][Full Text] [Related]
30. Robustness of Serologic Investigations for Chikungunya and Mayaro Viruses following Coemergence. Fischer C; Bozza F; Merino Merino XJ; Pedroso C; de Oliveira Filho EF; Moreira-Soto A; Schwalb A; de Lamballerie X; Netto EM; Bozza PT; Sarno M; Brites C; Gotuzzo E; Talledo M; Drexler JF mSphere; 2020 Feb; 5(1):. PubMed ID: 32024703 [TBL] [Abstract][Full Text] [Related]
32. Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose. Roy CJ; Adams AP; Wang E; Plante K; Gorchakov R; Seymour RL; Vinet-Oliphant H; Weaver SC J Infect Dis; 2014 Jun; 209(12):1891-9. PubMed ID: 24403555 [TBL] [Abstract][Full Text] [Related]
33. Pseudotyped viruses permit rapid detection of neutralizing antibodies in human and equine serum against Venezuelan equine encephalitis virus. Kolokoltsov AA; Wang E; Colpitts TM; Weaver SC; Davey RA Am J Trop Med Hyg; 2006 Oct; 75(4):702-9. PubMed ID: 17038698 [TBL] [Abstract][Full Text] [Related]
34. Boosting with an adenovirus-based vaccine improves protective efficacy against Venezuelan equine encephalitis virus following DNA vaccination. Perkins SD; O'Brien LM; Phillpotts RJ Vaccine; 2006 Apr; 24(17):3440-5. PubMed ID: 16527377 [TBL] [Abstract][Full Text] [Related]